The Cardiorenal Syndrome: A Review by Shah, B. N. & Greaves, K.
SAGE-HindawiAccess to Research
International Journal of Nephrology
Volume 2011, Article ID 920195, 11 pages
doi:10.4061/2011/920195
Review Article
TheCardiorenalSyndrome: A Review
B. N. Shah1 and K.Greaves2
1Department of Cardiology, Wessex Cardiothoracic Centre, Southampton University Hospital, Southampton, UK
2Department of Cardiology, Poole General Hospital and Bournemouth University, Longﬂeet Road, Poole, Dorset BH15 2JB, UK
Correspondence should be addressed to K. Greaves, kim.greaves@poole.nhs.uk
Received 13 September 2010; Accepted 21 November 2010
Academic Editor: Mitchell H. Rosner
Copyright © 2011 B. N. Shah and K. Greaves. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Cardiorenal syndrome (CRS) is the umbrella term used to describe clinical conditions in which cardiac and renal dysfunctions
coexist. Much has been written on this subject, but underlying pathophysiological mechanisms continue to be unravelled and
implications for management continue to be debated. A classiﬁcation system—incorporating ﬁve subtypes—has recently been
proposed though it has yet to permeate into day-to-day clinical practice. CRS has garnered much attention from both the
cardiological and nephrological communities since the condition is associated with signiﬁcant morbidity and mortality. Renal
dysfunctionishighlyprevalentamongstpatientswithheartfailureandhasbeenshowntobe aspowerful andindependentamarker
of adverse prognosis as ejection fraction. Similarly, patients with renal failure are considerably more likely to suﬀer cardiovascular
disease than matched subjects from the general population. This paper begins by reviewing the epidemiology and classiﬁcation
of CRS before going on to consider the diﬀerent pathological mechanisms underlying cardiorenal dysfunction. We then focus on
management strategies and conclude by discussing future directions in the diagnosis and management of patients suﬀering with
CRS.
1.Introduction
The heart is responsible for supplying the organs and tissues
of the body with blood, and the kidneys, amongst other
functions, play an integral role in ﬂuid balance and salt
homeostasis. It should therefore come as little surprise that
renal dysfunction frequently accompanies cardiac failure
and that cardiac dysfunction frequently accompanies renal
failure. This interdependent relationship has come to be
known as the “cardiorenal syndrome” [1]. This phrase has
been in use since 2004 [2], but despite generating a plethora
of papers in the literature and being discussed at length in
dedicated conferences, CRS has until very recently lacked a
universally accepted deﬁnition, and numerous key questions
remain unanswered [3]. What is the true prevalence? What
is the long-term prognosis? What is the exact underlying
pathophysiology? We shall cover the epidemiology, patho-
physiology, and current management of CRS in this paper,
but we will begin with brief case histories which help
demonstrate the heterogeneity of patients who fall under the
umbrella term of CRS.
Case 1. A 63-year-old patient with known severe heart
failure and chronic renal impairment (baseline creatinine
190mmol/L, estimated glomerular ﬁltration rate (eGFR)
23mLs/min) was admitted with acute decompensated heart
failure(ADHF).Creatinineonadmissionwassimilartobase-
line, but over the next week renal function deteriorated sig-
niﬁcantly (urea 51.1mmol/L, creatinine 503mmol/L, eGFR
8)requiringinotropicsupportandthenhaemoﬁltration.Her
inpatient stay lasted 7 weeks, of which over half was spent
on high dependency or intensive care units. Unfortunately,
she died from progressive pump failure several weeks after
admission.
Case 2. A 31-year-old previously ﬁt and well Indian man
was admitted with a two-week history of malaise and
a 2-day history of hemoptysis. Admission blood tests
revealed urea level of 20mmol/L and creatinine level of
1100mmol/L. Bedside echocardiography revealed moderate
global systolic dysfunction indicating probable uraemic
cardiomyopathy. A renal biopsy conﬁrmed the diagnosis
of glomerulonephritis. After his ﬁrst three sessions of2 International Journal of Nephrology
hemodialysis, echocardiography was repeated and revealed
normal systolic function.
Case 3. A 32-year-old lady developed end-stage renal failure
secondary to type 1 diabetes mellitus. She commenced
hemodialysis in 2007, and just prior to this, transthoracic
echocardiography revealed concentric ventricular hypertro-
phy and severely impaired systolic function. 6 months after
she had been started on hemodialysis, repeat echocardiogra-
phy revealed marked improvement in systolic function, with
LV dysfunction now only mild rather than severe.
Case 4. A 28-year-old ﬁt gentleman, with no past medical
history, was admitted feeling unwell for the past 3 days.
He was extremely ill when ﬁrst seen: temperature 40◦C,
BP 70/35mmHg, and pulse rate 130. Initial blood tests
revealedmarked leukocytosis(white cellcount41.5 × 109/L,
neutrophil count 38.5 × 109/L) and acute renal failure
(urea6.2mmol/Landcreatinine184mmol/L).Transthoracic
echocardiography revealed severely impaired systolic func-
tion. He was diagnosed with septic shock and treated with
ﬂuids and broad-spectrum intravenous antibiotics. In less
than 72 hours, he was feeling signiﬁcantly better and renal
functionhadreturnedtonormal.Numerousbloodandurine
culturesand throat swabs failed to yield a culpableorganism.
Repeat echocardiography one week later revealed normal
systolic function.
All of these patients had coexistent cardiac and renal
dysfunction but clearly with grossly diﬀerent underlying
pathology and, therefore, prognoses.
2.Epidemiology
Renal dysfunction is unfortunately extremely prevalent in
patients with congestive cardiac failure (CCF), and the asso-
ciated statistics make sombre reading. Data from the Acute
Decompensated Heart Failure National Registry (ADHERE)
of over 100,000 patients (admitted with ADHF) revealed
that almost one third of patients have a history of renal
dysfunction [4]. Another study found that, in a survey of
outpatients with congestive cardiac failure, 39% patients
in New York Heart Association (NYHA) class 4 and 31%
of patients in NYHA class 3 had severely impaired renal
function (creatinine clearance <30mls/minute) [5]. Baseline
renal function is as important an adverse prognostic marker
as ejection fraction and NYHA functional class [6]. Elevated
serum creatinine on admission to hospital with ADHF
and worsening renal function during admission for ADHF
have both been shown to predict prolonged hospitalisation,
increased need for intensive care facilities, and increased
mortality [7, 8].
Similarly, renal failure is clearly linked with increased
adverse cardiovascular outcomes. Almost 44% of deaths in
patients with end-stage renal failure (ESRF) are due to car-
diovascular diseases [9], and a 2006 meta-analysis indicated
that patients with ESRF are more likely to die from car-
diovascular causes than from renal failure itself [10]. Death
from cardiovascular causes is 10–20 times more common
in patients with chronic renal failure than in matched
segments of the general population [11]. Half of patients
commencinghemodialysis will suﬀeramyocardial infarction
within the following two years, and mortality in this patient
population is high [12]. Increased myocardial mass (i.e.,
left ventricular hypertrophy)—which increases myocardial
oxygendemand—is increased in mild-to-moderate as well as
more advanced stages of renal failure [13].
On the other hand, treatment of renal dysfunction
can improve cardiac function, although the majority of
this evidence comes from ESRF patients receiving kidney
transplants. A study of over100 dialysis patients with known
heart failure who underwent renal transplantation showed
an improvement of ejection fraction from 32% to 52% and
over two thirds of patients had complete normalisation of
cardiac function [14]. There are a few other such reports,
albeit, all in the transplant population [15–17].
3.Classiﬁcation:Cardiorenalor Renocardiac?
CRS has, in the absence of a generally accepted deﬁnition,
usually been perceived as renal dysfunction secondary to
chronic cardiac dysfunction (i.e., heart failure). However,
this clearly failed to address the numerous other instances
in which cardiac and renal dysfunction coexist. Ronco et
al. ﬁrst proposed a ﬁve-part classiﬁcation scheme for the
cardiorenal syndromes in 2008 [18], and this has since been
incorporated into the report from a consensus conference
held in the same year [19]. The classiﬁcation system is
outlined in Table 1 but essentially recognises the multiple
ways in which cardiorenal dysfunction occurs and deﬁnes
the primary and secondary organd y s f u n c t i o ni ne a c hc a s e .
This consensus group deﬁned CRS as “disorders of the heart
and kidneys whereby acute or chronic dysfunction in one
organ may induce acute or chronic dysfunction of the other”
[18]. This phraseology was chosen as it helps explain the
bi-directional nature of the various syndromes. Bongartz
and colleagues proposed the “cardiorenal connection” [20]
as an addition to the haemodynamic framework (on the
control of extracellular ﬂuid volume (ECFV)) developed
by the late physiologist Arthur Guyton and termed this
the “severe cardiorenal syndrome” (SCRS). They stated that
SCRS is a syndrome with “accelerated and extensive cardio-
vascular disease that has distinct properties not occurring
in conditions that aﬀect either organ alone” [20]. They
proposed the renin-angiotensin-aldosterone system (RAAS),
balance between nitric oxide (NO) and reactive oxygen
species (ROS), inﬂammation, and sympathetic nervous
system (SNS) as circuits within the cardiorenal connection.
Derangement of any connector was thought to initiate a
vicious downward spiral culminating in disturbance in the
other connectors and culminating in cardiac and renal
dysfunction via common ﬁnal pathophysiological pathways.
However, this terminology has not been widely adopted.
4.Pathophysiology
As our knowledge of CRS expands, it is becoming increas-
ingly clear how complex the interaction between heart andInternational Journal of Nephrology 3
Table 1: Schematic of the classiﬁcation system proposed by Ronco et al. [18] for subdivision of CRS into 5 subtypes based upon aetiology
of dysfunction.
CRS type Name Description Example
1 Acute cardiorenal Acute cardiac dysfunction leading to acute kidney
injury
Acute coronary syndrome causing acute heart
failure and then renal dysfunction
2 Chronic cardiorenal Chronic heart failure leading to renal dysfunction Congestive cardiac failure
3 Acute renocardiac Acute kidney injury leading to acute cardiac
dysfunction
Uraemic cardiomyopathy secondary to acute
renal failure
4 Chronic renocardiac Chronic renal failure leading to cardiac
dysfunction
Left ventricular hypertrophy and diastolic heart
failure secondary to renal failure
5S e c o n d a r y Systemic condition causing cardiac and renal
dysfunction Septic shock, vasculitis
kidneysisonceoneorganbecomesdiseased.Weshallexplore
these mechanisms in greater detail in this section of the
paper.
4.1. Old Paradigms Revisited: Beyond the Low-Flow Hypoth-
esis. Conventional thinking for decades held that the pro-
gressive deterioration in renal function in heart failure
patients was primarily as a result of reduced renal blood
ﬂow secondary to reduced cardiac output [21]. Inade-
quate renal aﬀerent ﬂow was said to activate the renin-
angiotensin-aldosterone system (RAAS) leading to ﬂuid
retention, increased preload, and thus worsening pump
failure. However, recent work suggests that, though correct,
this is a very narrow and incomplete picture.
The Evaluation Study of Congestive Heart Failure and
Pulmonary Artery Catheterization Eﬀectiveness (ESCAPE)
trial [22] assessed pulmonary artery catheter-guided man-
agement of over 400 patients admitted with ADHF. It
found no correlation between baseline renal function and
cardiac index, and improvement of the latter did not result
in improved renal function. Others have also found that
improved cardiac index or reduced wedge pressure during
pulmonary artery catheter-guided management failed to
predictimprovementinrenalfunction[23,24].Additionally,
worsening renal function has been demonstrated in ADHF
patients despite normal systolic function (ejection fraction)
[25], and thus, presumably, renal blood ﬂow. In combina-
tion, these data suggest much more than simply reduced
renal blood ﬂow as an explanation for CRS.
4.2. The Renin-Angiotensin-Aldosterone System (RAAS):
Friend Becomes Foe. Activation of the RAAS by reduced
perfusion pressure is a protective mechanism against poten-
tiallydangerousconditionslikehaemorrhage. Unfortunately,
when chronically stimulated—as in both heart and renal
failure—the pathophysiological consequences are severe
and deleteriously aﬀect function of both organ systems.
Renin is produced in the juxtaglomerular apparatus of the
kidneys and catalyses the conversion of angiotensinogen I
to angiotensinogen II, which is subsequently turned into
angiotensin II (Ang II) by angiotensin-converting enzyme
(ACE).
Ang IIhas numerous negative eﬀectsuponthe cardiovas-
cularsystem in heart failure patients,increasing bothpreload
and afterload and thus myocardial oxygen demands. The
main changes induced by Ang II are illustrated in Figure 1,
but one of the most important recent advances has been
recognition of the promotion of vascular inﬂammation [26].
A n gI Ia c t i v a t e st h ee n z y m eN A D P Ho x i d a s ei ne n d o t h e l i a l
cells, vascular smooth muscle cells [27], renal tubular cells
[28], and cardiomyocytes [29]. This leads to the formation
of ROS, mostly superoxide. A growing body of evidence
suggests that ROS are responsible for the processes of
aging, inﬂammation, and progressive organ dysfunction
[30]. Nitric oxide (NO) is responsible for vasodilation and
natriuresis and assists in renal control of ECFV. Superoxide
antagonises these eﬀects [31] but also reduces bioavailability
of NO. Oxidative stress damages DNA [32], proteins [33],
carbohydrates [34], and lipids [35] and also shifts cytokine
production towards proinﬂammatory mediators such as
interleukin-1, interleukin-6, and tumour necrosis factor
alpha [36]. Interleukin-6 also stimulates ﬁbroblasts leading
to increased cardiac and renal ﬁbrosis.
4.3. The Sympathetic Nervous System (SNS) in CRS. SNS
activationisinitiallyaprotectivemechanism inCCFpatients,
akin to RAAS activation. The aim is to maintain cardiac
output by positive chronotropic and inotropic eﬀects on
the myocardium. Unfortunately, chronic SNS activation
also results in numerous negative eﬀects upon the car-
diovascular system and kidneys. SNS overactivity leads to
reduction in beta-adrenoceptor density within myocardium
and also reduced adrenoceptor sensitivity in both renal
[37] and cardiac failure [38]. Catecholamines are also
thought to contribute to left ventricular hypertrophy seen
in some patients [39]. SNS activation leads to increased
cardiomyocyte apoptosis [40] and increases the release of the
neurohormone Neuropeptide Y (NPY). NPY is a vascular
growth promoter leading to neointimal formation (and
thus atherosclerosis) [41], induces vasoconstriction, and
also interferes with normal immune system function [42].
Renal sympathetic denervation in patients with resistant
hypertension signiﬁcantly improved renal function in one
quarterofpatients[43],andbilateralrenalnerveablationhas
been shown to reduce blood pressure at one-year followup4 International Journal of Nephrology
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Figure 1: Illustration of the pathophysiological pathways activated by angiotensin II. Both preload and afterload are ultimately increased,
leading to worsening cardiac and renal function (IL-6 = Interleukin 6; TNF-α = Tumour necrosis factor alpha; TGF-β = Transforming
growth Factor beta; ROS = Reactive oxygen species).
[44]. However, these therapies have not been tested in
the heart failure population and thus still requires further
evaluation.
4.4. Intraabdominal Hypertension: Underrecognised or Over-
emphasised? Heart failure is marked by an elevation in
centralvenouspressure which reducestheperfusion gradient
across the renal capillary bed. Studies performed in the early
partofthelast centurydemonstratedthatrising renal venous
pressures could reduce or even abolish urine production
[45], and rising renal venous pressure was more important
than falling arterial (perfusion) pressure in this setting.
Extrinsic compression of renal veins has also been shown to
compromise renal function [46].
Intraabdominal pressure (IAP) is said to be elevated
when >8mmHg, and intraabdominal hypertension has been
deﬁned as a pressure >12mmHg [47]. A study of 40 patients
admitted with ADHF found that 24 had an IAP >8mmHg
though none had abdominal symptoms. The degree of
reduction of IAP with diuretic treatment correlated with an
improvementinrenalfunction[48].TheESCAPEtrialfound
that baseline right atrial pressure, butnot arterial blood ﬂow,
correlated with baseline serum creatinine [22].
Patients with baseline renal dysfunction or worsening
renal function after admission have signiﬁcantly elevated
central venous pressure compared to those with less or
no renal dysfunction [49]. Additionally, elevated jugular
venous pressure on physical examination is associated with
higher baseline serum creatinine and increased risk of
hospitalisation due to ADHF and death due to pump failure
[50].
4.5. The Cardiorenal Anaemia Syndrome (CRAS). CRAS was
ﬁrst described almost a decade ago by Silverberg et al. as “a
vicious cycle of deterioration that leads to poor outcomes,
including faster progression to ESRF and further progres-
sion of congestive heart failure” [51]. Their simple model
suggested anaemia as a condition induced by dysfunction
of either organ but also exacerbating dysfunction of either
organ. Anaemia is present in over one-third of CRS patients
[52]. The Candesartan in Heart Failure: Assessment of
Reduction in Morbidity and Mortality (CHARM)study sug-
gested that anaemia was an independent adverse prognostic
factor inCCFpatients[53].There has, however,likeforCRS,
beenalackofconsensusoverthetruedeﬁnition,signiﬁcance,
and management strategy for patients with CRAS (if even
such a “syndrome” exists). This has mainly stemmed from
a lack of large-scale randomised controlled trials to guide
management.
Anaemia is widely thought to have a multifactorial
aetiology in patients with CKD or CCF, but iron deﬁciency
is thought to play a prominent role in both [54, 55].
Some evidence does suggest beneﬁt from treatment of iron
deﬁciency in such patients. The Ferinject Assessment in
patients with Iron deﬁciency and chronic Heart Failure
(FAIR-HF) study assessed intravenous (IV) iron therapy
in 459 symptomatic CCF patients with iron deﬁciency. It
demonstrated that the treatment group had a signiﬁcantInternational Journal of Nephrology 5
improvement in heart failure symptoms, exercise capacity,
and quality of life irrespective of whether they actually
had underlying anaemia or not [56]. Long-term safety
data on the newer dextrans-free IV preparations are still
awaited, but IV iron does appear to be emerging as an
important therapy in patients with CRAS. However, current
European guidelines for the management of heart failure
(published before results of trials such as FAIR-HF were
available) describe correction of anaemia in CCF patients as
“unproven” and “not established as routine therapy” [57].
The role of erythropoietin stimulating agents (ESAs) is
alsocontroversialduetoconﬂictingevidence.Erythropoietin
is a cytokine produced in the kidneys that is essential
for red blood cell production. Erythropoietin levels are
reduced in renal failure but frequently elevated in heart
failure. Scientiﬁc studies have shown that erythropoietin
protects cardiomyocytes from apoptosis [58, 59]a n dt h a t
the mechanism appears to be upregulation of endothelial
nitric oxide synthase [60]. A study of 26 heart failure
patients with anaemia who received ESA found signiﬁ-
cantly improved exercise capacity which appeared to be
principally due to increased oxygen delivery due to higher
haemoglobin concentration [61]. However, studies have
shown that patients with CCF have elevated endogenous
erythropoietin levels and that this is associated with poorer
survival independent of haemoglobin level [62, 63]. An
additional study showed that an erythropoietin level higher
than expected was an independent predictor of increased
mortality even after adjustment for possible confounding
variables [64]. Although initial small studies suggested
beneﬁt in correcting anaemia due to CKD with ESAs, three
large multicentre phase III trials all had negative outcomes
and put a severe question mark over the future of these
agents.The CardiovascularRiskReductionbyEarlyAnaemia
Treatment with Epoetin Beta (CREATE) trial found that
correcting anaemia early in patients with renal failure does
not reduce their risk of cardiovascular complications [65].
The Trial to Reduce Cardiovascular Events with Aranesp
Therapy (TREAT) study found that diabetic patients with
renal failure and moderate anaemia had no beneﬁt from
receiving ESA and in fact had a statistically higher risk
of stroke [66]. Finally, the Correction of Hemoglobin and
Outcomes in Renal Insuﬃciency (CHOIR) trial found that
aiming for a higher haemoglobin level in CKD patients
with anaemia was associated with a higher risk of adverse
outcomeincluding death, hospitalisation for heart failure, or
myocardial infarction [67]. A randomised trial of two dosing
regimens of the ESA darbepoetin alfa in patients with heart
failureand anaemia showed noimprovement in NYHAclass,
LV ejection fraction, or Minnesota Living with Heart Failure
questionnaire score [68]. Consequently, the routine use of
ESA therapy to increase haemoglobin levels in anaemic CCF
patients does not have a sound evidence base.
5.ManagementofCRS
Medical management of patients with concomitant cardiac
and renal dysfunction remains tremendously challenging,
and this is exacerbated by the fact that the vast majority
of trials providing evidence for treatments in heart failure
excluded patients with signiﬁcant renal impairment [69].
The heterogeneous nature of patients with CRS also poses
uniquechallenges with nosingle success-guaranteed therapy.
5.1. Diuretics: Not as Safe as Commonly Perceived? There is
limited trial data proving mortality beneﬁt for diuretics
in CRS, but they have long been deemed an essential
management strategy in these patients. Data from the
ADHERE registry suggests that 81% of patients were using
chronic diuretic therapy at the time of admission with
ADHF [4]. Studies have shown, however, that furosemide
decreases GFR in many patients [70], and higher doses of
diuretics are independently associated with sudden cardiac
death or death from pump failure [71, 72]. Furosemide
also stimulates the RAAS and can thus increase ﬁbrosis
[30]. A systematic review and meta-analysis on the use of
loop diuretics in management of patients with acute kidney
injury foundnomortality beneﬁt,thoughtherewasa shorter
required duration of renal replacement therapy [73]. A large
observational cohort study—examining the use of diuretics
in intensive care patients with acute renal failure—found
a signiﬁcantly increased risk of death or nonrecovery of
baseline renal function in the patients receiving diuretics
[74]. However, the two papers mentioned above looked at all
mechanisms of renal dysfunction, not just the heart failure
population. There is unfortunately a dearth of high-quality
randomised controlled evidence to support or refute the use
of diuretics in patients with cardiac and renal dysfunction.
Therefore, in the absence of deﬁnitive data proving harm in
heart failure population, diuretics should not be withheld
from volume-overloaded patients.
Diuretic resistance is frequently used as a surrogate
marker of poor prognosis in CCF patients. The most
probable culpable mechanisms are inadequate diuretic dose,
excessive sodium intake, delayed intestinal absorption due to
gutmucosaloedema, decreased diureticexcretion intourine,
and increased sodium reabsorption from other parts of the
nephronnotblockedbyloopdiuretics(e.g.,distalconvoluted
tubule) [75, 76]. Concomitant use of nonsteroidal anti-
inﬂammatory drugscanalso contributetodiureticresistance
by diminishing synthesis of vasodilator and natriuretic
prostaglandins [77].
In such patients there are several management options.
Firstly, one should bear in mind that furosemide does not
have a smooth dose-response curve, meaning that no natri-
uresis would occur until a threshold rate of drug excretion
is reached [78]. Consequently, a patient not responding to
40mg furosemide should have the dose doubled to 80mg
rather than the frequency doubled to twice daily. Secondly,
patients should be instructed to restrict their salt intake to
helpachievenetﬂuidloss.Thirdly,thepatientmayrequireIV
diuretic therapy to avoid the poor bioavailability frequently
encountered due to reduced gastrointestinal blood ﬂow,
reducedintestinal peristalsis, and intestinalmucosaloedema.
AC o c h r a n er e v i e w[ 79] has conﬁrmed that continuous IV
furosemide infusion achieves a greater diuresis than bolus6 International Journal of Nephrology
IV doses and this is associated with reduced mortality and
shorterhospitalstay.Othertreatmentoptionsincludeadding
in a thiazide diuretic to block distal sodium reabsorption,
a potassium-sparing diuretic such as spironolactone, or
adding salt-poor albumin. Salt-poor albumin is thought
to enhance delivery of furosemide to the kidney, and
one small study suggested adding salt-poor albumin to a
furosemideinfusion signiﬁcantly increased sodiumexcretion
[80].
5.2. Angiotensin-Converting Enzyme (ACE) Inhibitors. ACE
inhibitors are known to reduce mortality in patients with
heart failure [81], though the majority of these studies
excluded patients with signiﬁcant renal impairment. The
Cooperative North Scandinavian Enalapril Survival (CON-
SENSUS) study revealed that patients with the most severe
CCF had a substantial increase in creatinine on initiation
of an ACE inhibitor irrespective of baseline creatinine [82].
However, it is comforting to note that in the CONSENSUS
trial the outcomes were better in the treatment arm even
though mean creatinine increased. Indeed, some have pro-
posed that the rise in creatinine after initiation of an ACE
inhibitor actually may identify the subgroup of patients who
derive the most beneﬁt [83].
ACE inhibitors should be used with caution in patients
with CRS and renal functional monitored closely during
initiation and uptitration. This caution should not, however,
be used to avoid ACE inhibitor therapy. Studies have
shown that patients with ﬁrst presentation of pulmonary
oedema are frequently discharged without initiation of
ACE inhibitor therapy for fear of worsening renal function
[84]. However, as mentioned above, patients who derive
prognostic beneﬁt over the longer term from these drugs
may experience slight deterioration of renal function in the
short term. A concomitant reduction in diuretic dosage may
be required (especially once the patient is euvolemic) to
facilitate safe uptitration of the ACE inhibitor. The chances
ofdeteriorationofrenal functionafterstarting ACEinhibitor
therapy can also be minimised by avoiding simultaneous use
of NSAIDs and ensuring the patient is not hypovolemic at
onset of treatment.
5.3. Inotropic Support: The Controversy Continues. Patients
with CRS are often hypotensive, and admissions due to
ADHF frequently result in severe hypotensive episodes or
frank cardiogenic shock. This may be accompanied by oligo-
anuria, and inotropes are frequently used in this setting
with the aim of improving cardiac output and thus renal
blood ﬂow. “Renal” or low-dose dopamine is known to
increase renal blood ﬂow [85] though there is conﬂicting
evidence regarding its eﬀect upon GFR [85, 86]. One study
of 13 patients suggested that dopamine reduces renovascular
resistance [87], though the baseline renal function of these
patients is not stated. However, another larger study—in
which 75% had acute renal failure—showed an increase
in renovascular resistance in these patients with a fall in
resistance in those with normal renal function [88]. Most
importantly, no clinical trial to date has demonstrated a
mortality beneﬁt [89].
Trials of dobutamine and milrinone have shown
improvement of cardiac index and, in proportion, renal
blood ﬂow—however, this has not translated into mortality
beneﬁt. The Outcomes of a Prospective Trial of Intravenous
Milrinone for Exacerbationso faC h r o n i cH e a r tF a i l u r e
(OPTIME-HF) trial clearly rejected the hypothesis that
milrinone would improve renal function and overall survival
in ADHF patients [90].
The patient population who requires inotropic support
for ADHF or cardiogenic shock is inherently complex,
and thus designing adequately powered and well-conducted
randomised trials poses clear challenges. However, it seems
likely that short-term inotropic support for such patients in
a low-output state is likely to continue. Current ESC heart
failure guidelines state the evidence for using dobutamine as
class IIa level B, dopamine class IIa level C, milrinone class
IIb level B, and levosimendan class IIa level B (i.e., none has
a class I or level of evidence A recommendation) [57].
5.4. Nesiritide: Hope Turns to Hype? Certain pharmacological
agents—which held much promise during development—
have failed to make the expected impact following results
of phase III clinical trials. Nesiritide is an analogue of brain
natriuretic peptide (BNP) and known to induce vasodilation
and reduce ﬁlling pressures as well as augment cardiac
output. The ﬁrst large randomised trial of nesiritide in
patients with CRS demonstrated no diﬀerence in GFR, renal
plasma ﬂow, urine output, sodium excretion, or mortality
between treatment and placebo groups [91]. A meta-analysis
of seven large randomised trials of nesiritide also showed
a lack of mortality beneﬁt at 30-day and 180-day followup
[92]. A pooled analysis of three trials showed a strong
trend (P value .057) towards increased early mortality with
nesiritide [93]. The results of the Acute Study of Clinical
Eﬀectiveness of Nesiritide in Decompensated Heart Failure
Trial (ASCEND) [94] are currently awaited and may help
clarify if this agent has a future in the management of CRS
(type 2) patients.
6. FutureDirectionsin CRS
The ability to make a diagnosis of CRS early in a patient’s
assessment may allow early introduction of management
strategies which would hopefully prevent further clinical
and biochemical deterioration. Therefore, the development
of novel biomarkers of acute kidney injury is a promis-
ing step. Neutrophil gelatinase-associated lipocalin [95],
cystatin C [96], kidney injury molecule-1 [97], N-acetyl-
β-(D)glucosaminidase [98], and interleukin-18 [99]h a v e
all been shown to act as markers of renal injury in a
variety of diﬀerent clinical scenarios, and further work
is ongoing to help deﬁne their role in diagnosis and
management.
Patients resistant to diuretic therapy may beneﬁt from
ultraﬁltration (UF) or aquapheresis. This extracorporeal
treatment permits removal of large ﬂuid volumes moreInternational Journal of Nephrology 7
speedily than diuretics and without inducing profound
hypotension. The UNLOAD trial showed that, 48 hours after
treatment, UF safely produced greater weight and net ﬂuid
loss than conventional IV diuretic therapy and at 90 days
the UF group had fewer repeat admissions to hospital for
ﬂuid reaccumulation [100]. However, another trial demon-
strated that UF did not improve renal haemodynamics (as
judged by urine output, eGFR, and renal plasma ﬂow)
[101].
Arginine vasopressin (AVP) is released from the pos-
terior pituitary gland and mediates water retention via
the V2receptor in the renal collecting ducts. AVP levels
are elevated in heart failure patients and AVP antagonists
(the “vaptans”) have thus been developed. Tolvaptan was
initially shown to reduce body weight and help normalize
serum sodium in ADHF patients without adverse eﬀect on
blood pressure, heart rate, or renal function [102]. Later
studies also demonstrated that tolvaptan, when compared to
placebo, signiﬁcantly reduced pulmonary arterial pressure,
pulmonarycapillarywedgepressure,andrightatrialpressure
as well as increasing urine output without adverse eﬀect on
renal function [103]. The multicentre international phase
III Eﬃcacy of Vasopressin Antagonism in Heart Failure
Outcome Study with Tolvaptan (EVEREST) trial [104]
randomised patients admitted with ADHF within 48 hours
to receive either tolvaptan 30mg once daily or placebo for a
minimumtimedurationof60days.Tolvaptanwasassociated
with more weight loss and less dyspnoea on days 1 and 7 and
without adverse eﬀect on renal function. However, the key
end points of all-cause mortality, cardiovascular mortality,
cardiovascular death, or hospitalization, and worsening
heart failure were not diﬀerent between the two groups
[104].
Adenosine-A1 receptors are found in the kidney and
thought to mediate urine output. Adenosine levels are
increased in heart failure [105] and thus adenosine-A1
receptor antagonists were conceived; unfortunately, again,
thevitalrandomised trial failed toshow any beneﬁtin ADHF
patients [106].
CCF patients characteristically have an expanded extra-
cellular ﬂuid volume and contracted arterial blood volume
with resultant regional perfusion abnormalities. This results
in a series of complex neurohormonal changes leading to
peripheral and central congestion and reduced renal blood
ﬂow [107]. Hypertonic saline solution (HSS) has been
proposed as a useful adjunct to IV furosemide in ADHF
patients with CRS with several postulated mechanisms of
action: mobilisation of ﬂuid from the extravascular space
to the intravascular compartment by the osmotic eﬀects of
HSS and an increase in renal blood ﬂow which can thus
help overcome diuretic resistance [108]. Small studies have
demonstrated the abilityof HSSto augment renal blood ﬂow
and a larger trial—which randomised NYHA class 4 patients
to IV furosemide plus HSS or IV furosemide bolus alone—
revealed a greater degree of diuresis and natriuresis, lower
rehospitalisation rate, and lower mortality rate in the HSS
group versus placebo group [109]. However, routine use of
HSS in ADHF patients remains rare, and its role in this
patient population is yet to be deﬁned.
7.Conclusion
As our review has hopefully demonstrated, CRS is an
ominent development in many patients. However, prognosis
is not uniform across all ﬁve subtypes and highly dependent
upon the nature of the underlying disease process(es). The
worst prognoses are in those with chronic dysfunction of
both organ systems. CRS has generally been used so far
to describe patients with renal dysfunction secondary to
chronic heart failure; this group of patients have a par-
ticularly high morbidity and mortality. Diﬃculties remain
regarding diagnostic pathways and appropriate management
strategies. Fortunately, however, cardiologists and nephrolo-
gists are now acutely aware of the scale of the problem posed
by CRS, and this “awakening” will hopefully translate into
greater research into this fascinating yet challenging clinical
conundrum.
Conﬂictof Interests
The authors declare no conﬂict of interests.
Abbreviations
ACE: Angiotensin-converting enzyme
ADHF: Acute decompensated heart failure
AVP: Arginine vasopressin
BNP: Brain natriuretic peptide
CCF: Congestive cardiac failure
CKD: Chronic kidney disease
CRAS: Cardiorenal anaemia syndrome
CRS: Cardiorenal syndrome
ECFV: Extracellular ﬂuid volume
ESC: European Society of Cardiology
ESRF: End-stage renal failure
GFR: Glomerular ﬁltration rate
HSS: Hypertonic saline solution
IAP: Intraabdominal pressure
IV: Intravenous
LV: Left ventricle
NO: Nitric oxide
NPY: Neuropeptide Y
NSAID: Nonsteroidal anti-inﬂammatory drug
RAAS: Renin-angiotensin-aldosterone-system
ROS: Reactive oxygen species
SNS: Sympathetic nervous system
UF: Ultraﬁltration.
References
[1] J. T. Heywood, “The cardiorenal syndrome: lessons from
the ADHERE database and treatment options,” Heart Failure
Reviews, vol. 9, no. 3, pp. 195–201, 2005.
[2] NHLBI Working Group, “Cardiorenal connections in heart
failure and cardiovascular disease,” National Heart, Lung
andBloodInstituteWebsite,October 2009,http://www.nhlbi
.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm.
[3] C. Geisberg and J. Butler, “Addressing the challenges of
cardiorenal syndrome,” Cleveland Clinic Journal of Medicine,
vol. 73, no. 5, pp. 485–491, 2006.8 International Journal of Nephrology
[ 4 ]K .F .A d a m sJ r . ,G .C .F o n a r o w ,C .L .E m e r m a ne ta l . ,
“Characteristics and outcomes of patients hospitalised for
heart failure in the United States: rationale, design and
preliminary observations from the ﬁrst 100,000 cases in
the Acute Decompensated Heart Failure National Registry
(ADHERE),” American Heart Journal, vol. 149, pp. 209–216,
2005.
[ 5 ]F .A .M c A l i s t e r ,J .E z e k o w i t z ,M .T o n e l l i ,a n dP .W .A r m -
strong,“Renal insuﬃciency andheart failure: prognostic and
therapeutic implications from a prospective cohort study,”
Circulation, vol. 109, no. 8, pp. 1004–1009, 2004.
[6] M. G. Shlipak and B. M. Massie, “The clinical challenge
of cardiorenal syndrome,” Circulation, vol. 110, no. 12, pp.
1514–1517, 2004.
[ 7 ]H .L .H i l l e g e ,A .R .J .G i r b e s ,P .J .d eK a me ta l . ,“ R e n a l
function, neurohormonalactivation, and survival in patients
with chronic heart failure,” Circulation, vol. 102, no. 2, pp.
203–210, 2000.
[ 8 ] D .E .F o r m a n ,J .B u t l e r ,Y .W a n ge ta l . ,“ I n c i d e n c e ,p r e d i c t o r s
atadmission,andimpactofworseningrenalfunctionamong
patients hospitalized with heart failure,” Journal of the
American College of Cardiology, vol. 43, no. 1, pp. 61–67,
2004.
[9] National Institutes of Health, “National Institute of Diabetes
and Digestive and Kidney diseases,” Annual Data Report,
USRDS, Bethesda, Md, USA, 1997, http://www.usrds.org/.
[10] M. Tonelli, N. Wiebe, B. Culleton et al., “Chronic kidney
diseaseand mortalityrisk: a systematicreview,” Journal of the
American SocietyofNephrology,vol.17,no.7,pp. 2034–2047,
2006.
[11] A. E. G. Raine, R. Margreiter, F. P. Brunner et al., “Report
on management of renal failure in Europe, XXII, 1991,”
Nephrology Dialysis Transplantation, vol. 7, no. 2, pp. 7–35,
1992.
[ 1 2 ]C .A .H e r z o g ,J .Z .M a ,a n dA .J .C o l l i n s ,“ P o o rl o n g - t e r m
survival after acute myocardial infarction among patients on
long-term dialysis,” New England Journal of Medicine,v o l .
339, no. 12, pp. 799–805, 1998.
[ 1 3 ]K .G r e a v e s ,R .C h e n ,L .G ee ta l . ,“ M i l dt om o d e r a t er e n a l
impairment is associated with increased left ventricular
mass,”International Journal of Cardiology, vol. 124, no. 3, pp.
384–386, 2008.
[ 1 4 ]R .K .W a l i ,G .S .W a n g ,S .S .G o t t l i e be ta l . ,“ E ﬀect of kidney
transplantation on left ventricular systolic dysfunction and
congestive heart failure in patients with end-stage renal
disease,” Journal of the American College of Cardiology,v o l .
45, no. 7, pp. 1051–1060, 2005.
[15] P. S. Parfrey, J. D. Harnett, R. N. Foley et al., “Impact of
renal transplantation on uremic cardiomyopathy,” Trans-
plantation, vol. 60, no. 9, pp. 908–914, 1995.
[16] R. K. Burt, S. Gupta-Burt, W. N. Suki, C. G. Barcenas, J. J.
Ferguson, and C. T. van Buren, “Reversal of left ventricular
dysfunction after renal transplantation,” Annals of Internal
Medicine, vol. 111, no. 8, pp. 635–640, 1989.
[17] S. R. C. Ferreira, V. A. Mois´ es, A. Tavares, and A. Pacheco-
Silva, “Cardiovascular eﬀects of successful renal transplanta-
tion: a 1-year sequential study of left ventricular morphology
and function, and 24-hour blood pressure proﬁle,” Trans-
plantation, vol. 74, no. 11, pp. 1580–1587, 2002.
[ 1 8 ]C .R o n c o ,M .H a a p i o ,A .A .H o u s e ,N .A n a v e k a r ,a n dR .
Bellomo, “Cardiorenal syndrome,” Journal of the American
College of Cardiology, vol. 52, no. 19, pp. 1527–1539, 2008.
[19] C. Ronco, P. McCullough, S. D. Anker et al., “Cardio-renal
syndromes: report from the consensus conference of the
acute dialysis quality initiative,” European Heart Journal,v o l .
31, no. 6, pp. 703–711, 2010.
[ 2 0 ]L .G .B o n g a r t z ,M .J .C r a m e r ,P .A .D o e v e n d a n s ,J .A .J o l e s ,
and B. Braam, “The severe cardiorenal syndrome: ’Guyton
revisited’,” European Heart Journal, vol. 26, no. 1, pp. 11–17,
2005.
[21] P. J. Cannon, “The kidney in heart failure,” New England
Journal of Medicine, vol. 296, no. 1, pp. 26–32, 1977.
[22] A. Nohria, V. Hasselblad, A. Stebbins et al., “Cardiorenal
interactions. Insights from the ESCAPE trial,” Journal of the
American College of Cardiology, vol. 51, no. 13, pp. 1268–
1274, 2008.
[ 2 3 ]M .S .W e i n f e l d ,G .M .C h e r t o w ,a n dL .W .S t e v e n s o n ,
“Aggravated renal dysfunction during intensive therapy for
advanced chronic heart failure,” American Heart Journal,v o l .
138, no. 2, pp. 285–290, 1999.
[24] W. Mullens, Z. Abrahams, G. S. Francis et al., “Importance
of venous congestion for worsening of renal function in
advanced decompensated heart failure,” Journal of the Amer-
ican College of Cardiology, vol. 53, no. 7, pp. 589–596, 2009.
[25] C. W. Yancy, M. Lopatin, L. W. Stevenson, T. de Marco,
and G. C. Fonarow, “Clinical presentation, management,
and in-hospital outcomes of patients admitted with acute
decompensatedheartfailurewithpreservedsystolicfunction:
a report from the Acute Decompensated Heart Failure
National Registry (ADHERE) database,” Journal of the Amer-
ican College of Cardiology, vol. 47, no. 1, pp. 76–84, 2006.
[ 2 6 ]M .E .P u e y o ,W .G o n z a l e z ,A .N i c o l e t t i ,F .S a v o i e ,J .F .
Arnal,andJ.B.Michel,“AngiotensinIIstimulatesendothelial
vascular cell adhesion molecule-1 via nuclear factor-κB
activation induced by intracellular oxidative stress,” Arte-
riosclerosis, Thrombosis, and Vascular Biology,v o l .2 0 ,n o .3 ,
pp. 645–651, 2000.
[27] M. Ushio-Fukai, A. M. Zafari, T. Fukui, N. Ishizaka, and
K. K. Griendling, “p22(phox) is a critical component of
the superoxide-generating NADH/NADPH oxidase system
andregulates angiotensinII-induced hypertrophy invascular
smooth muscle cells,” Journal of Biological Chemistry,v o l .
271, no. 38, pp. 23317–23321, 1996.
[28] T.Chabrashvili,C.Kitiyakara,J.Blauetal.,“Eﬀects ofANGII
type 1 and 2 receptors on oxidative stress, renal NADPH oxi-
dase, and SOD expression,” American Journal of Physiology—
Regulatory Integrative and Comparative Physiology, vol. 285,
no. 1, pp. R117–R124, 2003.
[ 2 9 ]H .N a k a g a m i ,M .T a k e m o t o ,a n dJ .K .L i a o ,“ N A D P H
oxidase-derived superoxide anion mediates angiotensin II-
induced cardiac hypertrophy,” Journal of Molecular and
Cellular Cardiology, vol. 35, no. 7, pp. 851–859, 2003.
[30] J. S. Bock and S. S. Gottlieb, “Cardiorenal syndrome: new
perspectives,” Circulation, vol. 121, no. 23, pp. 2592–2600,
2010.
[31] A. P. Zou, N. Li, and A. W. Cowley Jr., “Production and
actions of superoxide in the renal medulla,” Hypertension,
vol. 37, no. 2, pp. 547–553, 2001.
[ 3 2 ] V .W i t k o - S a r s a t ,M .F r i e d l a n d e r ,T .N .K h o ae ta l . ,“ A d v a n c e d
oxidation protein products as novel mediators of inﬂam-
mation and monocyte activation in chronic renal failure,”
Journal of Immunology, vol. 161, no. 5, pp. 2524–2532, 1998.
[33] V. Witko-Sarsat, M. Friedlander, C. Capeill` ere-Blandin et al.,
“Advanced oxidation protein products as a novel marker of
oxidative stress in uremia,” Kidney International, vol. 49, no.
5, pp. 1304–1313, 1996.
[34] T. Miyata, K. Maeda, K. Kurokawa, and C. van Ypersele
de Strihou, “Oxidation conspires with glycation to generateInternational Journal of Nephrology 9
noxious advanced glycation end products in renal failure,”
Nephrology Dialysis Transplantation, vol. 12, no. 2, pp. 255–
258, 1997.
[35] E. Maggi, R. Bellazzi, A. Gazo, M. Seccia, and G. Bellomo,
“Autoantibodies against oxidatively-modiﬁed LDL in uremic
patients undergoing dialysis,” Kidney International, vol. 46,
no. 3, pp. 869–876, 1994.
[36] M. F. Hill and P. K. Singal, “Antioxidant and oxidative
stress changes during heart failure subsequent to myocardial
infarction in rats,” American Journal of Pathology, vol. 148,
no. 1, pp. 291–300, 1996.
[37] K. Leineweber, I. Heinroth-Hoﬀmann, K. P¨ onicke, G. Abra-
h a m ,B .O s t e n ,a n dO .E .B r o d d e ,“ C a r d i a cβ-adrenoceptor
desensitizationdue toincreased β-adrenoceptor kinaseactiv-
ity in chronic uremia,” Journal of the American Society of
Nephrology, vol. 13, no. 1, pp. 117–124, 2002.
[38] M. R. Bristow, R. Ginsburg, W. Minobe et al., “Decreased
catecholamine sensitivity and β-adrenergic-receptor density
in failing human hearts,” New England Journal of Medicine,
vol. 307, no. 4, pp. 205–211, 1982.
[ 3 9 ]J .K .A m i n ,L .X i a o ,D .R .P i m e n t a le ta l . ,“ R e a c t i v e
oxygenspecies mediatealpha-adrenergicreceptor-stimulated
hypertrophy in adult rat ventricular myocytes,” Journal of
MolecularandCellular Cardiology,vol.33,no.1,pp.131–139,
2001.
[ 4 0 ] G .J a c k s o n ,C .R .G i b b s ,M .K .D a v i e s ,a n dG .Y .L i p ,“ A B Co f
heart failure. Pathophysiology,” British Medical Journal,v o l .
320, no. 7228, pp. 167–170, 2000.
[ 4 1 ]L .L i ,E .W .L e e ,H .J i ,a n dZ .Z u k o w s k a ,“ N e u r o p e p t i d e
Y-induced acceleration of postangioplasty occlusion of rat
carotid artery,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 23, no. 7, pp. 1204–1210, 2003.
[42] Z. Zukowska-Grojec, “Neuropeptide Y—A novel sympa-
thetic stress hormone and more,” Annals of the New York
Academy of Sciences, vol. 771, pp. 219–233, 1995.
[43] H. Krum, M. Schlaich, R. Whitbourn et al., “Catheter-based
renal sympathetic denervation for resistant hypertension: a
multicentre safety and proof-of-principle cohort study,” The
Lancet, vol. 373, no. 9671, pp. 1275–1281, 2009.
[44] M. P. Schlaich, P. A. Sobotka, H. Krum, E. Lambert, and M.
D. Esler, “Renal sympathetic-nerve ablation for uncontrolled
hypertension,” New England Journal of Medicine,vol.361,no.
9, pp. 932–934, 2009.
[45] F. R. Winton, “The inﬂuence of venous pressure on the
isolated mammalian kidney,” Journal of Physiology,v o l .7 2 ,
pp. 49–61, 1931.
[46] S.E.BradleyandG. P.Bradley, “The eﬀect ofincreased intra-
abdominal pressure on renal function in man,” Journal of
Clinical Investigation, vol. 26, pp. 1010–1015, 1947.
[47] M. L. N. G. Malbrain, M. L. Cheatham, A. Kirkpatrick et
al., “Results from the international conference of experts on
intra-abdominal hypertension and abdominal compartment
s y n d r o m e .I .D e ﬁ n i t i o n s , ”Intensive Care Medicine, vol. 32,
no. 11, pp. 1722–1732, 2006.
[48] W.Mullens,Z.Abrahams,H.N.Skourietal.,“Elevatedintra-
abdominal pressure in acute decompensated heart failure. A
potential contributor to worsening renal function?” Journal
of the American College of Cardiology, vol. 51, no. 3, pp. 300–
306, 2008.
[49] K. Damman, V. M. van Deursen, G. Navis, A. A. Voors, D. J.
van Veldhuisen, and H. L. Hillege, “Increased central venous
pressure is associated with impaired renal function and
mortalityinabroadspectrum ofpatientswithcardiovascular
disease,”JournaloftheAmerican CollegeofCardiology,vol.53,
no. 7, pp. 582–588, 2009.
[50] M. H. Drazner, J. E. Rame, L. W. Stevenson, and D. L. Dries,
“Prognostic importance of elevated jugular venous pressure
and a third heart sound in patients with heart failure,” New
England Journal of Medicine, vol. 345, no. 8, pp. 574–581,
2001.
[51] D. S. Silverberg, D. Wexler, M. Blumet al., “The correction of
anemia in severe resistant heart failure with erythropoietin
and intravenous iron prevents the progression of both the
heart and the renal failure and markedly reduces hospital-
ization,” Clinical Nephrology, vol. 58, pp. S37–S45, 2002.
[52] R. P. Silva, P. H. U. Barbosa, O. S. Kimura et al., “Prevalance
of anemia and its association with cardio-renal syndrome,”
International Journal of Cardiology, vol. 120, no. 2, pp. 232–
236, 2007.
[53] E. O’Meara, T. Clayton, M. B. McEntegart et al., “Clinical
correlates and consequences of anemia in a broad spectrum
of patients with heart failure—results of the candesartan
in heart failure: assessment of reduction in mortality and
morbidity (CHARM) program,” Circulation, vol. 113, no. 7,
pp. 986–994, 2006.
[ 5 4 ]L .G o t l o i b ,D .S i l v e r b e r g ,R .F u d i n ,a n dA .S h o s t a k ,“ I r o n
deﬁciency is a common cause of anemia in chronic kidney
disease and can often be corrected with intravenous iron,”
Journal of Nephrology, vol. 19, no. 2, pp. 161–167, 2006.
[55] J. N. Nanas, C. Matsouka, D. Karageorgopoulos et al.,
“Etiology of anemia in patients with advanced heart failure,”
Journal of the American College of Cardiology, vol. 48, no. 12,
pp. 2485–2489, 2006.
[56] S. D. Anker, J. C. Colet, G. Filippatos et al., “Ferric carboxy-
maltose in patients with heart failure and iron deﬁciency,”
New England Journal of Medicine, vol. 361, no. 25, pp. 2436–
2448, 2009.
[57] K. Dickstein, A. Cohen-Solal, G. Filippatos et al., “ESC
Guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008,” European Heart Journal, vol. 29,
no. 19, pp. 2388–2442, 2008.
[58] L. Calvillo, R. Latini, J. Kajstura et al., “Recombinant human
erythropoietin protects the myocardium from ischemia-
reperfusion injury and promotes beneﬁcial remodeling,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 8, pp. 4802–4806, 2003.
[59] C. J. Parsa, A. Matsumoto, J. Kim et al., “A novel protective
eﬀect of erythropoietin in the infarcted heart,” Journal of
Clinical Investigation, vol. 112, no. 7, pp. 999–1007, 2003.
[60] D. Burger, M. Lei, N. Geoghegan-Morphet, X. Lu, A.
Xenocostas, and Q. Feng, “Erythropoietin protects car-
diomyocytes from apoptosis via up-regulation of endothelial
nitric oxide synthase,” Cardiovascular Research,v o l .7 2 ,n o .1 ,
pp. 51–59, 2006.
[61] D. M. Mancini, S. D. Katz, C. C. Lang, J. LaManca, A.
Hudaihed, and A. S. Androne, “Eﬀect of erythropoietin on
exercise capacity in patients with moderate to severe chronic
heart failure,” Circulation, vol. 107, no. 2, pp. 294–299, 2003.
[ 6 2 ]P .v a nd e rM e e r ,A .A .V o o r s ,E .L i p s i c ,T .D .J .S m i l d e ,W .
H. van Gilst, and D. J. van Veldhuisen, “Prognostic value of
plasma erythropoietin on mortality in patients with chronic
heart failure,” Journal of the American College of Cardiology,
vol. 44, no. 1, pp. 63–67, 2004.
[63] J. George, S. Patal, D. Wexler et al., “Circulating erythropoi-
etin levels and prognosis in patients with congestive heart
failure comparison with neurohormonal and inﬂammatory10 International Journal of Nephrology
markers,” Archives of Internal Medicine, vol. 165, no. 11, pp.
1304–1309, 2005.
[64] P. van der Meer, D. J. Lok, J. L. Januzzi et al., “Adequacy of
endogenous erythropoietin levels and mortality in anaemic
heart failure patients,” European Heart Journal, vol. 29, no.
12, pp. 1510–1515, 2008.
[65] T. B. Drueke, F. Locatelli, N. Clyne et al., “Normalization of
haemoglobin level in patients with chronic kidney disease
and anaemia,”New England Journal of Medicine, vol. 355, pp.
2071–2084, 2006.
[66] M. A. Pfeﬀer, E. A. Burdmann, C. Y. Chen et al., “A trial
of darbepoetin alfa in type 2 diabetes and chronic kidney
disease,” New England Journal of Medicine, vol. 361, no. 21,
pp. 2019–2032, 2009.
[67] A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of
anemia with epoetin alfa in chronic kidney disease,” New
England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098,
2006.
[68] D. J. van Veldhuisen, K. Dickstein, A. Cohen-Solal et al.,
“Randomized, double-blind, placebo-controlled study to
evaluatetheeﬀect oftwo dosingregimens ofdarbepoetin alfa
in patients with heart failure and anaemia,” European Heart
Journal, vol. 28, no. 18, pp. 2208–2216, 2007.
[69] M.G.Shlipak,“Pharmacotherapyforheartfailureinpatients
with renal insuﬃciency,” Annals of Internal Medicine,v o l .
138, no. 11, pp. 917–924, 2003.
[70] S. S. Gottlieb, D. C. Brater, I. Thomas et al., “BG9719 (CVT-
124), an A1 adenosine receptor antagonist, protects against
the decline in renal function observed with diuretic therapy,”
Circulation, vol. 105, no. 11, pp. 1348–1353, 2002.
[71] J. Butler, D. E. Forman, W. T. Abraham et al., “Relationship
between heart failure treatment and development of wors-
ening renal function among hospitalized patients,” American
Heart Journal, vol. 147, no. 2, pp. 331–338, 2004.
[72] G. W.Neuberg, A. B. Miller, C. M. O’Connoret al.,“Diuretic
resistance predicts mortality in patients with advanced heart
failure,” American Heart Journal, vol. 144, no. 1, pp. 31–38,
2002.
[73] S. M. Bagshaw, A. Delaney, M. Haase, W. A. Ghali, and R.
Bellomo, “Loop diuretics in the management of acute renal
failure: a systematic review and meta-analysis,” Critical Care
and Resuscitation, vol. 9, no. 1, pp. 60–68, 2007.
[74] R. L. Mehta, M. T. Pascual, S. Soroko, and G. M. Chertow,
“Diuretics, mortality, and nonrecovery of renal function
in acute renal failure,” Journal of the American Medical
Association, vol. 288, no. 20, pp. 2547–2553, 2002.
[75] D. H. Ellison, “Diuretic drugs and the treatment of edema:
from clinic to bench and back again,” American Journal of
Kidney Diseases, vol. 23, no. 5, pp. 623–643, 1994.
[ 7 6 ] D .C .B r a t e r ,B .D a y ,A .B u r d e t t e ,a n dS .A n d e r s o n ,
“Bumetanide and furosemide in heart failure,” Kidney Inter-
national, vol. 26, no. 2, pp. 183–189, 1984.
[77] D. C. Brater, “Analysis of the eﬀect of indomethacin on the
responseto furosemide inman:eﬀect of dose offurosemide,”
Journal of Pharmacology and Experimental Therapeutics,v o l .
210, no. 3, pp. 386–390, 1979.
[78] N. Pokhrel, N. Maharjan, B. Dhakal, and R. R. Arora,
“Cardiorenal syndrome: a literature review,” Experimental
and Clinical Cardiology, vol. 13, no. 4, pp. 165–170, 2008.
[79] D. R. Salvador, N. R. Rey, G. C. Ramos, and F. E. Punzalan,
“Continuous infusionversusbolusinjectionofloopdiuretics
in congestive heart failure,” Cochrane Database of Systematic
Reviews, no. 1, Article ID CD003178, 2004.
[80] M. Inoue, K. Okajima, K. Itoh et al., “Mechanism of
furosemide resistance in analbuminemic rats and hypoalbu-
minemic patients,” Kidney International,v o l .3 2 ,n o .2 ,p p .
198–203, 1987.
[81] The SOLVD investigators, “Eﬀect of enalapril on survival in
patients with reduced left ventricular ejection fractions and
congestive heart failure,” New England Journal of Medicine,
vol. 325, pp. 293–302, 1992.
[82] S. Ljungman, J. Kjekshus, and K. Swedberg, “Renal function
in severe congestive heart failure during treatment with
Enalapril (the Cooperative North Scandinavian Enalapril
Survival Study [CONSENSUS] trial),” American Journal of
Cardiology, vol. 70, no. 4, pp. 479–487, 1992.
[83] G.L.BakrisandM.R.Weir,“Angiotensin-convertingenzyme
inhibitor-associated elevations in serum creatinine: is this a
cause for concern?” Archives of Internal Medicine, vol. 160,
no. 5, pp. 685–693, 2000.
[84] M. Echemann, F. Zannad, S. Brianc ¸on et al., “Determinants
of angiotensin-converting enzyme inhibitor prescription in
severe heart failure with left ventricular systolic dysfunction:
the EPICAL study,” American Heart Journal, vol. 139, no. 4,
pp. 624–631, 2000.
[85] R .H .M c D onald ,L.I .G old b e r g,J .L.M c N a y ,andE .P .T u t t le ,
“Eﬀects of dopamine in man: augmentation of sodium
excretion, glomerular ﬁltration rate and renal plasma ﬂow,”
Journal of Clinical Investigation,vol.43,pp. 1116–1124,1964.
[86] B. Ramdohr, G. Biamino, and R. Schr¨ oder, “Vergleichende
Untersuchungen ¨ uber die Wirkung von Dopamin und
Orciprenalin am gesunden Menschen: Muskeldurchblutung,
Nierendurchblutung, Nierenfunktion,” Klinische Wochen-
schrift, vol. 50, no. 3, pp. 149–157, 1972.
[87] U. Elkayam, T. M. H. Ng, P. Hatamizadeh, M. Janmohamed,
and A. Mehra, “Renal vasodilatory action of dopamine in
patients with heart failure: magnitude of eﬀect and site of
action,” Circulation, vol. 117, no. 2, pp. 200–205, 2008.
[88] A. Lauschke, U. Teichgr¨ aber, U. Frei, and K. U. Eckardt,
“’Low-dose’ dopamine worsens renal perfusion in patients
with acute renal failure,” Kidney International, vol. 69, no. 9,
pp. 1669–1674, 2006.
[89] P. Marik, “Low-dose dopamine: a systematic review,” Inten-
sive Care Medicine, vol. 28, no. 7, pp. 877–883, 2002.
[90] L. Klein, B. M. Massie, J. D. Leimberger et al., “Admission or
changes in renal function during hospitalization for worsen-
ing heart failure predict post discharge survival: results from
theOutcomesofaProspectiveTrialofIntravenousMilrinone
for Exacerbations of Chronic Heart Failure (OPTIME-
CHF),” Circulation: Heart Failure, vol. 1, pp. 25–33, 2008.
[ 9 1 ]D .J .W a n g ,T .C .D o w l i n g ,D .M e a d o w se ta l . ,“ N e s i r i t i d e
does not improve renal function in patients with chronic
heart failure and worsening serum creatinine,” Circulation,
vol. 110, no. 12, pp. 1620–1625, 2004.
[92] R. R. Arora, P. K. Venkatesh, and J. Molnar, “Short and long-
term mortality with nesiritide,” American Heart Journal,v o l .
152, no. 6, pp. 1084–1090, 2006.
[93] J. D. Sackner-Bernstein, M. Kowalski, M. Fox, and K.
Aaronson, “Short-term risk of death after treatment with
nesiritide for decompensated heart failure: a pooled analysis
of randomized controlled trials,” Journal of the American
Medical Association, vol. 293, no. 15, pp. 1900–1905, 2005.
[94] A. F. Hernandez, C. M. O’Connor, R. C. Starling et al.,
“Rationale and design of the Acute Study of Clinical Eﬀec-
tiveness of Nesiritide in Decompensated Heart Failure Trial
(ASCEND-HF),” American Heart Journal, vol. 157, no. 2, pp.
271–277, 2009.International Journal of Nephrology 11
[95] K. Mori and K. Nakao, “Neutrophil gelatinase-associated
lipocalin as the real-time indicator of active kidney damage,”
Kidney International, vol. 71, no. 10, pp. 967–970, 2007.
[96] S. Herget-Rosenthal, G. Marggraf, J. H¨ using et al., “Early
detection of acute renal failure by serum cystatin C,” Kidney
International, vol. 66, no. 3, pp. 1115–1122, 2004.
[ 9 7 ]V .S .V a i d y a ,V .R a m i r e z ,T .I c h i m u r a ,N .A .B o b a d i l l a ,a n dJ .
V. Bonventre, “Urinary kidney injury molecule-1: a sensitive
quantitative biomarker for early detection of kidney tubular
injury,” American Journal of Physiology—Renal Physiology,
vol. 290, no. 2, pp. F517–F529, 2006.
[98] O. Liangos, M. C. Perianayagam, V. S. Vaidya et al., “Urinary
N-acetyl-β-(D)-glucosaminidase activity and kidney injury
molecule-1 level are associated with adverse outcomes in
acute renal failure,” Journal of the American Society of
Nephrology, vol. 18, no. 3, pp. 904–912, 2007.
[ 9 9 ]C .R .P a r i k h ,A .J a n i ,V .Y .M e l n i k o v ,S .F a u b e l ,a n dC .L .
Edelstein, “Urinary interleukin-18 is a marker of human
acute tubular necrosis,” American Journal of Kidney Diseases,
vol. 43, no. 3, pp. 405–414, 2004.
[100] M. R. Costanzo, M. E. Guglin, M. T. Saltzberg et al.,
“Ultraﬁltration versus intravenous diuretics for patients
hospitalized for acute decompensated heart failure,” Journal
of the American College of Cardiology, vol. 49, no. 6, pp. 675–
683, 2007.
[101] H. L. Rogers, J. Marshall, J. Bock et al., “A randomized, con-
trolled trial of the renal eﬀects of ultraﬁltration as compared
to furosemide in patients with acute decompensated heart
failure,” Journal of Cardiac Failure, vol. 14, no. 1, pp. 1–5,
2008.
[102] M. Gheorghiade, I. Niazi, J. Ouyang et al., “Vasopressin V2-
receptor blockade with tolvaptan in patients with chronic
heart failure: results from a double-blind, randomized trial,”
Circulation, vol. 107, no. 21, pp. 2690–2696, 2003.
[103] J. E. Udelson, C. Orlandi, J. Ouyang et al., “Acute hemo-
dynamic eﬀects of tolvaptan, a vasopressin V2 receptor
blocker, in patients with symptomatic heart failure and sys-
tolic dysfunction: an international,multicenter, randomized,
placebo-controlled trial,” Journal of the American College of
Cardiology, vol. 52, no. 19, pp. 1540–1545, 2008.
[104] M. A. Konstam, M. Gheorghiade, J. C. Burnett Jr. et
al., “Eﬀects of oral tolvaptan in patients hospitalized for
worseningheartfailure:theEVERESToutcometrial,”Journal
of the American Medical Association, vol. 297, no. 12, pp.
1319–1331, 2007.
[105] H. Funaya, M. Kitakaze, K. Node, T. Minamino, K. Koma-
mura, and M. Hori, “Plasma adenosine levels increase in
patients with chronic heart failure,” Circulation, vol. 95, no.
6, pp. 1363–1365, 1997.
[106] G. Cotter, H. C. Dittrich, B. Davison Weatherley et al., “The
PROTECT pilot study: a randomized, placebo-controlled,
dose-ﬁnding study of the adenosine A1 receptor antagonist
rolofylline in patients with acute heart failure and renal
impairment,” Journal of Cardiac Failure,v o l .1 4 ,n o .8 ,p p .
631–640, 2008.
[107] M. Packer, “Neurohormonal interactions and adaptations in
congestive heart failure,” Circulation, vol. 77, no. 4, pp. 721–
730, 1988.
[108] S.Paterna,P.DiPasquale,G.Parrinelloetal.,“Eﬀectsofhigh-
dose furosemide and small-volume hypertonic saline solu-
tion infusion in comparison with a high dose of furosemide
as a bolus, in refractory congestive heart failure,” European
Journal of Heart Failure, vol. 2, no. 3, pp. 305–313, 2000.
[109] G. Licata,P.Di Pasquale,G. Parrinello et al.,“Eﬀects of high-
dose furosemide and small-volume hypertonic saline solu-
tion infusion in comparison with a high dose of furosemide
as bolus in refractory congestive heart failure: long-term
eﬀects,” American Heart Journal, vol. 145, no.3, pp. 459–466,
2003.